Effect of Oral Intake of Sodium Benzoate on Serum Cholesterol and Proinflammatory Cytokine (Tumor Necrosis Factor Alpha [TNF-α] and Interleukin-6 [IL-6]) Levels in the Heart Tissue of Wistar Rats

Main Article Content

Efekemo, Oghenetekevwe
Akaninwor, Joyce Oronne
Essien, Eka Bassey

Abstract

The in vivo effect of oral administration of varying concentrations (150, 250, 500 mg/kg body wt.) of sodium benzoate (a known preservative in the food, cosmetic and pharmaceutical industry) on serum cholesterol and proinflammatory markers in heart tissue of wistar albino rats were investigated. The oral intake was administered at 24 hour intervals for 7, 14, 21 and 28 days. The groups were labelled; control (group 1), 7days (group 2), 14days (group 3), 21 days (group 4) and 28days (group 5). The rats were fed normal diet ad libitum and blood sample for the determination was taken at the end of the duration. For serum cholesterol, the result obtained for sodium benzoate concentrations administered showed significant (p≤0.05) decrease in cholesterol levels at group 5 for 250 mg/kg body wt. and grp 2, 3, 4 and 5 for 500 mg/kg body wt of experimental rats. The proinflammatory cytokines TNF-α and IL-6 of heart tissue showed significant decrease at grp 4 and 5 for 250 mg/kg body wt and 2, 3, 4 and 5 for 500 mg/kg body wt. values were all compared to control. These findings suggest modulation of the inflammatory pathway due to administration of the preservative.

Keywords:
Sodium benzoate, cholesterol, serum, proinflammatory cytokines.

Article Details

How to Cite
Oghenetekevwe, E., Oronne, A. J., & Bassey, E. E. (2019). Effect of Oral Intake of Sodium Benzoate on Serum Cholesterol and Proinflammatory Cytokine (Tumor Necrosis Factor Alpha [TNF-α] and Interleukin-6 [IL-6]) Levels in the Heart Tissue of Wistar Rats. Asian Journal of Research in Biochemistry, 5(2), 1-8. https://doi.org/10.9734/ajrb/2019/v5i230086
Section
Original Research Article

References

Cheesbrough M. Medical laboratory manual for tropical countries. 2nd edition. Tropical Health Technology and Butterworth Scientific Limited. 1991;1:494-526.

Baldwin EA, Nisperos-Carriedo MO, Baker RA. Use of edible coatings to preserve quality of lightly (and slightly) processed products. Critical Review on Food Science and Nutrition. 1995;35(6):509-524.

Ishida H. Levels of preservatives in toothpastes and possibility of their intake during brushing of teeth. Shokuhin Eiseigaku Zasshi. Journal of Food Hygiene Society of Japan. 1996;37:234-239.

Villanueva MBG, Jonai H, Kanno S, Takeuchi Y. Dietary sources and background levels of hippuric acid in urine: Comparison of Philippine and Japanese levels. Industrial Health. 1994;32:239-249.

Nair B. Final report on the safety assessment of Benzyl Alcohol, Benzoic Acid and Sodium Benzoate. International Journal of Toxicology. 2001;20(3):23-50.

Kubota K, Ishizaki T. Dose-dependent pharmacokinetics of benzoic acid following oral administration of sodium benzoate to humans. European Journal of Clinical Pharmacology. 1991;41:363-368.

Leonard JV, Morris AA. Urea cycle disorders. Seminar Neonatology. 2002;7: 27–35.

Scaglia F, Carter S, O’Brien WE, Lee B. Effect of alternative pathway therapy on branched chain amino acid metabolism in urea cycle disorder patients. Molecular and Genetic Metabolism. 2004;81(1):S79–S85.

Toth B. Lack of tumorigenicity of sodium benzoate in mice. Fundamental of Applied Toxicology. 1984;4:494-496.

Brahmachari S, Jana A, Pahan K. Sodium benzoate, a metabolite of cinnamon and a food additive, reduces microglial and astroglial inflammatory responses. Journal of Immunology. 2009; 183(9):5917–27.

Fujitani T. Short-term effect of sodium benzoate in F344 rats and B6C3F1 mice. Toxicology Letters. 1993;69:171-179.

Vogt T, Landthaler M, Stolz W. Sodium benzoate-induced acute leukocytoclastic vasculitis with unusual clinical appearance. Archives of Dermatology. 1999;135:726-727.

Sodemoto Y, Enomoto M. Report of carcinogenesis bioassay of Sodium benzoate in rats: absence of carcinogenicity of sodium benzoate in rats. Journal of Environmental Pathology, Toxicology and Oncology. 1980;4:87-95.

Chipley JR. Sodium benzoate and benzoic acid. In: Branen AL, Davidson PM, eds. Antimicrobials in foods. New York, M. Decker. 1983;11-35.

European Commission. European Union Directive 95/2/CE from 20.02.1995 on food additives, colourants and sweeteners. European Commission; 1995.

Kwiterovich PO. The metabolic pathways of high-density lipoprotein, low-density lipoprotein and triglycerides: A current review". The American Journal of Cardiology. 2000;86(12A):5L–10L.

Shekhar M, Pramod RS, Vankatesh KV. Control of cholesterol homeostasis by entero-hepatic bile transport – The role of feedback mechanisms. Royal society of chemistry. 2014;4:58964-58975.

Yakubu MT, Akanji MA, Oladiji AT. Alterations in serum lipid profile of male rats by oral administration of aqueous extract of Fadogia agrestis stem. Research Journal of Medicinal Plants. 2008;2:66–73.

Saurabh K, kalipada P. Sodium benzoate, a metabolite of cinnamon and a food additive, upregulates neuroprotective Parkinson disease protein DJ-1 in astrocytes and neurons. Journal of Immunology and Pharmacology. 2012;7 (2):424–435.

Boguski MS, McCormick F. Proteins regulating Ras and its relatives. Nature.1993;366:643–654.

Laufs U, Liao JK. Direct vascular effects of HMG-CoA reductase inhibitors. Trends in Cardiovascular Medicine. 2000;10:143–148.

Takai Y, Sasaki T, Matozaki T. Small GTP-binding proteins. Physiological Review. 2001;81:153–208.

Hancock JF, Cadwallader K, Marshall CJ. Methylation and proteolysis are essential for efficient membrane binding of prenylated p21K-ras (B). EMBO Journal. 1991;10:641–646.

Kikuchi A, Williams LT. The post-translational modification of ras p21 is important for raf-1 activation. Journal of Biological Chemistry. 1994;269:20054–20059.

Garnovskaya MN, Van Biesen T, Hawe B, Casanas-Ramos S, Lefkowitz RJ, Raymond JR. Ras-dependent activation of fibroblast mitogen-activated protein kinase by 5-HT1A receptor via a G protein beta gamma-subunit-initiated pathway. Biochemistry. 1996;35:13716–13722.

Qiu RG, Chen J, Kirn D, McCormick F, Symons M. An essential role for Rac in Ras transformation. Nature. 1995;374: 457–459.

Heymans S, Corsten MF, Verhesen W. Macrophage microRNA-155 promotes cardiac hypertrophy and failure. Circulation. 2013;128(13):1420–32.

Jana A, Pahan K. Oxidative stress kills human primary oligodendrocytes via neutral sphingomyelinase: Implications for multiple sclerosis. Journal of Neuroimmune Pharmacology. 2007;2:184–193.

Jana A, Pahan K. Fibrillar amyloid-beta-activated human astroglia kill primary human neurons via neutral sphingomyelinase: Implications for Alzheimer’s disease. Journal of Neuroscience. 2010;30:12676–12689.

Kleinert H, Wallerath T, Fritz G, Ihrig-Biedert I, Rodriguez-Pascual F, Geller DA, Forstermann U. Cytokine induction of NO synthase II in human DLD-1 cells: Roles of the JAK-STAT, AP-1 and NF-κB-signaling pathways. Britain Journal of Pharmacology. 1998;125:193–201.

Liu X, Jana M, Dasgupta S, Koka S, He J, Wood C, Pahan K. (Human immunodeficiency virus type 1 (HIV-1) Tat induces nitric-oxide synthase in human astroglia. Journal of Biological Chemistry. 2002;277:39312–39319.

Pahan K, Jana M, Liu X, Taylor BS, Wood C, Fischer SM. Gemfibrozil, a lipid-lowering drug, inhibits the induction of nitric-oxide synthase in human astrocytes. Journal of Biological Chemistry. 2002;277: 45984–45991.

Pahan K, Liu X, McKinney MJ, Wood C, Sheikh FG, Raymond JR. Expression of a dominant-negative mutant of p21ras inhibits induction of nitric oxide synthase and activation of nuclear factor-kappaB in primary astrocytes. Journal of Neurochemistry. 2000;74:2288–2295.

Yang J. Cardiac-specific overexpression of farnesyl pyrophosphate synthase induces cardiac hypertrophy and dysfunction in mice. Cardiovascular Research. 2013;97: 490-499.

Yang J. Inhibition of farnesyl pyrophosphate synthase attenuates angiotensin II-induced cardiac hypertrophy and fibrosis in vivo. International Journal of Biochemistry and Cell Biology. 2013;45: 657–666.

Kuusisto J, Kärjä V, Sipola P. Low-grade inflammation and the phenotypic expression of myocardial fibrosis in hypertrophic cardiomyopathy. Heart. 2012; 98(13):1007–13.

Erten Y, Tulmac M, Derici U, Pasaoglu H, Reis KA, Bali MN, Sindel S. An association between inflammatory state and left ventricular hypertrophy in hemodialysis patients. Renal Failure. 2005;27(5):581-589.

Hilfiker-Kleiner D, Shukla P, Klein G, Continuous glycoprotein-130-mediated signal transducer and activator of transcription-3 activation promotes inflammation, left ventricular rupture, and adverse outcome in subacute myocardial infarction. Circulation. 2010;122(2):145–55.

Hirota H, Yoshida K, Kishimoto T, Taga T. Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proceedings of the National Academy of Science, USA. 1995;92(11): 4862–66.

Velten M, Duerr GD, Pessies T. Priming with synthetic oligonucleotides attenuates pressure overload-induced inflammation and cardiac hypertrophy in mice. Cardiovascular Research. 2012;96(3):422–32.

Heymans S, Hirsch E, Anker SD. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure. 2009;11(2):119–29.